Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,201–12,300 of 15,747
Riccò, M., Valente, M., Dalmonte, G., Marchesi, F., Peruzzi, S., Ballabeni, L., & Prioriello, C. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i3.12386 · Cited by 1
“To date (i.e. September 2021) several formulates have benefited from Emergency Use Authorization from Western European and North-American Health Authorities, including innovative mRNA-based formulates (i.e. Comirnaty from Pfizer/BioNTech and Spikevax from Moderna) (6,7), and adenovirus-based formulates (i.e. Ad26.”
BackgroundWinkeljann, B., Lapuhs, P., Alonso, M. J., & Kımna, C. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114911 · Cited by 3
Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19
Ohno, M., Sekiya, T., Obeng-Kyeremeh, R., Handabile, C., Haruta, M., Nomura, N., Kawakita, T., Shingai, M., & Kida, H. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127173 · Cited by 2
Vaccines against COVID-19 – Catching the Rays of Hope
Srinivasamurthy, S. K., & Bairy, L. K. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i47a33035 · Cited by 1
“BNT 162b2 evaluated in multinational placebo controlled observer blinded pivotal efficacy trial (NCT04368728) [58].”
BackgroundMethodPrompetchara, E., Ketloy, C., Alameh, M.-G., Tarakhet, K., Kaewpang, P., Yostrerat, N., Pitakpolrat, P., Buranapraditkun, S., Manopwisedcharoen, S., Thitithanyanont, A., et al. (2022) · doi:10.1101/2022.09.07.506878 · Cited by 1
“Among the recently approved vaccines, the mRNA modality seems to be the most efficacious as it induces high levels of desired immune responses and protects from severe symptoms (16, 17).”
BackgroundRNA therapeutics for infectious diseases
Tu, L. M. T. P. P. L. M., Pham, T. T. D., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.002 · Cited by 1
Using extracted data from Kaplan-Meier curves to compare COVID-19 vaccine efficacyPreprint
Tansawet, A., Numthavaj, P., Oranratnachai, S., et al. (2023) · medRxiv · doi:10.1101/2023.04.19.23288799 · Cited by 1
“1 % and 95% for mRNA-1273 and BNT162b2, respectively (Baden et al., 2020; Polack et al., 2020).”
BackgroundDang, C. M., Kemp, T. J., Roche, N., Haynesworth, K., Loftus, S. A., Borski, B. J., Bakouny, Z., Labaki, C., Lee, G. M., Trowbridge, R., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2570963 · Cited by 1
Shah, A. A., Rashmi, K., Kumar, V., Kumar, N., & Gupta, A. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.sp200 · Cited by 1
Baber, R. (2021) · Climacteric · doi:10.1080/13697137.2021.1985308 · Cited by 1
“Effective vaccines have been developed at a pace faster than ever before in our history [2] and almost 7000 clinical trials and 180,000 papers related to COVID-19 have been conducted.”
BackgroundCarobene, A., Famiglini, L., Sabetta, E., Naclerio, A., & Banfi, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-08506-2_5 · Cited by 1
Li, Y., Luo, R., Li, Y., Liu, Z., Duan, X., Qin, S., He, Z., & Liu, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119888 · Cited by 3
Ethical Principles in Legal Context: Vaccine Mandates During the COVID-19 Pandemic in Australia
Thomasson, A., Williams, J., Drislane, S., & Rizzi, M. (2026) · Journal of Bioethical Inquiry · doi:10.1007/s11673-026-10570-8 · Cited by 1
Vilela, L., Silva, A. G., Cruz, A. S., Sousa, M., Costa, M., Fonseca, F., Campino, S. G., Clark, T. G., & Miranda, A. (2024) · Vaccines · doi:10.3390/vaccines12121358 · Cited by 1
Neurovaskuläre Manifestationen von COVID‑19
Veltkamp, R. C., Purrucker, J. C., & Weber, R. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01104-1 · Cited by 1
(2022) · doi:10.1101/2022.06.06.494494 · Cited by 1
“Thus, the S protein is the antigenic component of vaccine design 66 (21-23).”
BackgroundHaire, B. G. (2021) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2021.020 · Cited by 2
Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection
Grunst, M. W., Li, W., & Mothes, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1733684 · Cited by 1
Nanovaccines against viral infections: Current trends and future prospects
Khan, S., Belgamwar, A. V., & Yeole, P. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99596-2.00014-5 · Cited by 1
COVID-19 Vaccine in Renal Transplant Recipients: A Bibliometric-Based Analysis of Trends
Wang, D., Zhou, C., Wang, C., Guo, S., Zhang, Y., Lv, H., & Zhou, F. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.06.013 · Cited by 1
The effect of outcome choice on vaccine dose allocation: a modelling study
Burch, E., Christensen, H., & Brooks‐Pollock, E. (2025) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2025.112156 · Cited by 2
(2021) · doi:10.1101/2021.05.03.21256525 · Cited by 1
“8 Vaccine Characteristics – Wild Type First dose efficacy against clinical infection 85% starting 15 days after receipt of first dose Observed effectiveness among healthcare workers in Israel (25) Second dose efficacy against clinical infection 95% starting 10 days after receipt of second dose Pfizer phase III vaccine…”
Mathew, J., George, L. E., Paul, S., Joy, A., & Peradi, S. (2023) · Conservative Dentistry and Endodontic Journal · doi:10.5005/jp-journals-10048-0108 · Cited by 1
Expanding Perspectives on Integrative Medicine: Promoting Global Health in the COVID-19 Era
Shin, J. (2022) · Perspectives on Integrative Medicine · doi:10.56986/pim.2022.09.001 · Cited by 1
“Advances in conventional medicine such as the development of vaccines [1-3], and antiviral therapies [4-6] has made it possible to manage the COVID-19 global crisis.”
BackgroundRen, Z., Furukawa, K., Nishimura, M., Kurahashi, Y., Sutandhio, S., Tjan, L. H., Aoki, K., Hasegawa, N., Arii, J., Uto, K., et al. (2021) · medRxiv · doi:10.1101/2021.09.26.21264129 · Cited by 2
A case of autoimmune hepatitis following administration of the COVID19 vaccine
Yagi, S., Tamai, J., Watanabe, T., Yoshida, M., Tokumoto, Y., Abe, M., Murakami, K., Satou, M., Niida, K., Miyamoto, Y., et al. (2022) · Kanzo · doi:10.2957/kanzo.63.491 · Cited by 1
A genetically engineered, stem-cell-derived cellular vaccine
Cooper, A., Sidaway, A., Chandrashekar, A., Latta, E., Chakraborty, K., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100843 · Cited by 2
From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery
Wu, W., Wei, Z., & Peng, X. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04622-9 · Cited by 3
“In the trials of BNT162b2 of BioNtech, the case split corresponds to 95.0% vaccine efficacy (95% confidence interval [CI], 90.3 to 97.6) [23] and mRNA-1273 of Moderna [24].”
InfluentialYoon, S. K., Phillips, A. L., Calhoun, S., et al. (2025) · medRxiv · doi:10.1101/2025.08.25.25334392 · Cited by 1
Karofi, D. H., Lawal, N., Bello, M. B., & Imam, M. U. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00965-y · Cited by 1
Kamamuta, A., Yuki, T., Takahashi, M., Kurihara, K., Shibata, H., Tanaka, K., & Hata, K. (2022) · medRxiv · doi:10.1101/2022.12.02.22282982 · Cited by 1
Zhu, Z., Li, J., Lu, Q., Zeng, W., Yu, Z., Liu, N., Zhang, Z., Wang, Z., Yang, N., Chen, Y., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04319-z · Cited by 2
“The success of coronavirus disease 2019 (COVID-19) mRNA vaccines [24, 25] has begun to foster the development of mRNA vaccines against other infectious diseases and different types of cancer [26, 27].”
Claes, M., Genet, B., Rouet, A., Boutitie, L., Parramore, P., Hardy, É., Thomas, C., Zerah, L., & Vallet, H. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05240-6 · Cited by 1
“Furthermore, vaccines were developed and were found effective in reducing the risk of severe forms of the disease [31, 32].”
BackgroundAlgaba, A., Romero, S., Granja, A., Garza, D., Aller, M. D. M., Barrero, S., Guerra, I., Gil, M., Pizarro, N., Ruiz, P., et al. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.05.006 · Cited by 1
Respiratory mucosal immunity: Biological functions, diseases, prevention and therapy
Yu, Z., Song, Z., Hong, W., He, X., & Wei, X. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102200 · Cited by 1
3D-printed simulator for nasopharyngeal swab collection for COVID-19
Koch, A., Vermel, M., Hansmann, Y., Lodi, M., Mura, C., Sananès, A., Gallien, S., Wurtz, É., Bleibtreu, A., Martinot, M., et al. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.02.002 · Cited by 2
Lewis, J. W., Loughran, J., Deng, L., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2811.221043 · Cited by 1
Transmission of B.1.617.2 Delta Variant Between Vaccinated Healthcare WorkersPreprint
Kemp, S. A., Cheng, M. T. K., Hamilton, W., Kamelian, K., Singh, S. K., Rakshit, P., Aggrawal, A., Illing, C. J. R., & Gupta, R. K. (2022) · Research Square · doi:10.21203/rs.3.rs-1166169/v1 · Cited by 1
Elliott, P., Haw, D., Wang, H., Eales, O. D., Walters, C. E., Ainslie, K. E. C., Atchison, C. J., Fronterrè, C., Diggle, P. J., Page, A. J., et al. (2021) · Cited by 1
Factors associated with COVID-19 vaccine acceptance among medical laboratory workers in South Africa
Motlhale, M., Wilson, K. S., Jones, D. T., et al. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i1.1291 · Cited by 1
“38,39 Therefore, assumptions that the most vulnerable would automatically accept COVID-19 vaccination are unfounded, highlighting the need for healthcare team members to initiate discussions focusing on the vaccine’s impact on an individual’s underlying condition.”
Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem
Galitskaya, M. G., Fisenko, А. P., & Makarova, S. G. (2022) · Russian Pediatric Journal · doi:10.46563/1560-9561-2022-25-2-139-146 · Cited by 1
Mairhofer, M., Kausche, L., Kaltenbrunner, S., Pammer, M., Ghanem, R., Stegemann, M., & Schmitt, C. A. (2025) · iScience · doi:10.1016/j.isci.2025.113727 · Cited by 1
“…spike protein-directed vaccines such as BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) significantly lowered the risk of severe COVID-19, 3,4 we and others reported responses to a basal immunization with these vaccines to be less profound in patients with tumor (T), especially in…”
InfluentialAbera, B. T., Teka, H., Berhe, E., Abrha, M., Zenebe, D., Abraha, H. E., & Hailu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-53561-8 · Cited by 1
Kim, K. S., Jung, I. H., & Byun, J. H. (2024) · Complexity · doi:10.1155/2024/3357763 · Cited by 1
Wang, R., Mathes, S., Claussen, C., Biedermann, T., & Brockow, K. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14987_g · Cited by 1
Essien, E. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2442ed · Cited by 1
Factors Affecting Parental Intent to Vaccinate Against COVID-19 in Kansas
Duncan, L., Hoang, M., Magathan, L., Sliefert, M., McKaughan, K., Loo-Gross, C., & Ofei‐Dodoo, S. (2025) · Kansas Journal of Medicine · doi:10.17161/kjm.vol18.22762 · Cited by 1
Prunas, O., Willemsen, J. E., Warren, J. L., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100509 · Cited by 1
Chiwandire, N., Walaza, S., von Gottberg, A., Wolter, N., du Plessis, M., Moosa, F., Groome, M. J., Nel, J. S., Variava, E., Dawood, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3423529/v1 · Cited by 1
Clinical Trials in the Development of Vaccines for Infectious Diseases
Lockhart, S., & Gruber, W. C. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162572-00050 · Cited by 1
Self-citationHow could our genetics impact COVID-19 vaccine response?
Zheng, K., Chong, A. Y.-Y., & Mentzer, A. J. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2346584 · Cited by 3
“The primary vaccines that have been administered widely to the public and thus have been a significant focus of research studies to date include the BNT162b2 vaccine (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) [29,31].”
Non-invasive quantitative chemical measurements of liposomal formulations using Raman spectroscopy
Legge, E. J., Coones, R. T., Lee, W. A., Pei, Y., Belsey, N. A., & Minelli, C. (2025) · RSC Pharmaceutics · doi:10.1039/d4pm00238e · Cited by 2
Zanlourensi, C. B., & Boing, A. F. (2025) · Epidemiologia e Serviços de Saúde · doi:10.1590/s2237-96222025v34e20240329.pt · Cited by 2
Hirano, H. (2025) · Cureus · doi:10.7759/cureus.95359 · Cited by 1
“The efficacy of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) was initially demonstrated in randomized controlled trials [2], which subsequently led to global vaccination campaigns worldwide.”
Chi, H., An, K., He, J., Du, Y., Yang, S., Wang, Y., Liu, X., Li, Y., Shu, M., Zheng, M., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01652-4 · Cited by 2
Gerß, J., & Vonthein, R. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0035 · Cited by 2
Adverse Events Following COVID 19 Vaccine Shot
Lathamangeswari, C., Pandurangan, H., Ramaiah, P., & Muthukrishnan, A. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.sp206 · Cited by 1
Fülöp, T., Larbi, A., Khalil, A., Hirokawa, K., Cohen, A. A., & Witkowski, J. M. (2022) · Lessons from the ICU · doi:10.1007/978-3-030-94133-8_6 · Cited by 1
Post-acute non-specific symptoms following COVID-19 vaccination: a Danish population-based study
Jensen, C. B., Hansen, K. T., Bech, B. H., Hansen, S. N., Nielsen, H. I., Rask, C. U., Fink, P., Dantoft, T. M., Jørgensen, T., Labrecque, J. A., et al. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf173 · Cited by 1
Predicting Covid-19 Protein Interactions Through Sequence Alignment
Raheem, A. K. A., & Dhannoon, B. N. (2024) · Communications in computer and information science · doi:10.1007/978-3-031-62814-6_11 · Cited by 1
Ohira, M., Osada, T., Kimura, H. J., Sano, T., & Takao, M. (2023) · eNeurologicalSci · doi:10.1016/j.ensci.2023.100487 · Cited by 1
The macroeconomic and epidemiological impacts of Covid-19 in PakistanPreprint
Jensen, H. T., Keogh-Brown, M. R., Eggo, R. M., Pearson, C. A. B., Rueda, S. T., Huda, M., Khalid, M., Zulfiqar, W., CMMID COVID-19 Working Group, Smith, R., et al. (2023) · medRxiv · doi:10.1101/2023.10.06.23296657 · Cited by 1
Kurata, Y., INOUE, N., KONDO, S., Onozawa, K., Tani, N., Minami, J., Oishi, R., Nagano, S., Araki, H., & Kuwano, H. (2022) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.96.65 · Cited by 1
Klessing, S., Peter, A. S., Fraedrich, K., Wagner, J. T., Kummer, M., Deutschmann, J., Steininger, P. A., Steibl, H.-D., & Überla, K. (2023) · Viruses · doi:10.3390/v15020397 · Cited by 2
Tiwari, P. N., & Kushwaha, A. S. (2022) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_428_22 · Cited by 1
Mohammed, R. A., Yazbik, R. S., Baajajah, L. H., Alharthy, S. F., Alsalahi, H., Mahjaa, M. A., Barakat, M. M., Badawy, M. I., & Sultan, I. E. (2023) · Cureus · doi:10.7759/cureus.34030 · Cited by 2
“3% of the recipients reported lymphadenopathy [16], while the AstraZeneca vaccine phase 3 clinical trials did not report any cases of lymphadenopathy [17].”
BackgroundCaicedo, M. S., Flores, V., Siapno, R., Crosby, M., Samelko, L., Jacobs, J. J., & Hallab, N. J. (2023) · Journal of Orthopaedics · doi:10.1016/j.jor.2023.11.041 · Cited by 1
COVID-19 Outcomes Among People With HIV and COVID-19 in New York CityPreprint
Braunstein, S. L., Wahnich, A., & Lazar, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4016534 · Cited by 1
The Potential of mRNA Vaccines to Fight Against Viruses
Wang, X. (2024) · Viral Immunology · doi:10.1089/vim.2024.0047 · Cited by 2
Arora, P., Gupta, N., Rathee, D., & Jimmy, J. K. (2022) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2022/23 · Cited by 1
Attitudes of health care workers toward COVID-19 vaccination: A literature review
Łaskawiec-Żuławińska, D., Wlazło, M., Grajek, M. K., & Korzonek-Szlacheta, I. (2023) · Applied Psychology Research · doi:10.59400/apr.v2i1.347 · Cited by 1
“Since the outbreak of the COVID-19 pandemic, the first vaccine was developed and then marketed in less than a year [14] .”
BackgroundTwo-birds-one-stone approach to combine protein and mRNA vaccines for COVID-19
Gao, G. F. (2023) · Nature Immunology · doi:10.1038/s41590-023-01539-5 · Cited by 1
COVID‐19 vaccines for rapid global impact
Hill, A. V. S. (2021) · British Journal of Urology · doi:10.1111/bju.15339 · Cited by 1
Anafilaxia causada por vacunas
Perea-Valle, P., Delgado-Aguirre, C. J., Villafuerte-Domínguez, B. G., & Del-Rio-Navarro, B. E. (2022) · Revista Alergia México · doi:10.29262/ram.v69isupl1.989 · Cited by 4
Williams, L., Ferguson, N., Donnelly, C., & Grassly, N. (2021) · medRxiv · doi:10.1101/2021.07.30.21260912 · Cited by 12
“Rearranging equation (1) and substituting equation (3) into equation (1) then provides a solution for VEpr”
Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., Takeuchi, J. S., Horii, K., Ozeki, M., et al. (2022) · medRxiv · doi:10.1101/2022.06.21.22276682 · Cited by 1
“%) patients among PCR-confirmed COVID-19 cases.”
InfluentialRahbar, M., Sharifi, Y., & Aghamir, S. M. K. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103517 · Cited by 1
Garg, R., Liu, Q., van Kessel, J., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4793115 · Cited by 1
Laake, J. H., Hagen, M., Aavitsland, P., Buanes, E. A., Fjone, K. S., Kvåle, R., Olsen, B. F., & Hofsø, K. (2025) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.70027 · Cited by 2
“9,10 These factors were further influenced by the introduction of new or modified therapeutics, 11 – 13 vaccines 14 – 16 and emerging viral variants.”
Silva, L. C. M., Limeira, L. Q., Galhardo, L. M., da Silva, M. A. O., de Andrade, L. H. C., Martins, J. Z., dos Santos, L. L., MATTEI, M. B. Q., & Santos, P. H. P. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i8.5609 · Cited by 1
Hori, S., Tomizawa, M., Yoneda, T., et al. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.09.031 · Cited by 1
System immunoinformatics–based design of a multi-epitope vaccine candidate against La Crosse virus
Masum, M. H. U., Heema, H. P., Mahdeen, A. A., Lokman, S. M., Tasnim, Z., Hasan, M. R., Arpa, S. H., Parvin, R., Ferdous, J., & Uddin, M. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350287 · Cited by 3
Ergören, M. Ç., Akan, G., Volkan, E., Kandemiş, E., Evren, E. Ü., Evren, H., Volkan, E., Tuncel, G., Süer, K., & Şanlıdağ, T. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28309 · Cited by 2
“Messenger RNA (mRNA)‐based vaccines by Pfizer/BioNTech (BNT162b2), Moderna (mRNA‐1273), led to high (94%–95%) efficacy in Phase III trials, supported by real world data.(3,4) Similarly, adenovirus vector‐based vaccines from University of Oxford/ AstraZeneca (ChAdOx1 nCoV‐19 vaccine [AZD1222]) and Janssen (Ad26.”
BackgroundClinical adverse events following COVID-19 vaccination: a scoping review of observational studies
Rodríguez, C. A. C., Guerrero, J. A. S., Rivadeneira, L. C. C. H., Robles, A. M. C., Cañarte, P. D. T., Salazar, G. N. M., Moreira, J. J. C., Castro, F. A. L., Molina-Recalde, A. P., & Córdova, V. M. Á. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20254397 · Cited by 1
Current state of COVID-19 in pregnancy
Sinchikhin, S. P., Bragina, G. S., Parshina, O. V., et al. (2022) · GYNECOLOGY · doi:10.26442/20795696.2022.3.201671 · Cited by 1
“Начальные исследования по применению вакцин показывали, что наиболее эффективными по ответной реакции иммунной системы с выработкой специфических антител (более чем 90%) являлись российская вакцина «Cпутник V» и американская вакцина компании Pfizer [23, 24].”
COVID-19 Vaccines in the Pediatric Population: A Focus on Cardiac Patients
Lababidi, G. H., Lababidi, H., Bitar, F. F., & Arabi, M. T. (2024) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2024/2667033 · Cited by 1
Mair, M. J., Mitterer, M., Buratti, T., Berchtold, L., Fong, D., & Preusser, M. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101559 · Cited by 1
Escasas y probables complicaciones neurológicas de las vacunas contra el Sars-Cov-2
Guevara-Silva, E. A., & Castro‐Suárez, S. (2021) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v84i3.4031 · Cited by 1
Tougeron, D., Seitz‐Polski, B., Hentzien, M., Bani‐Sadr, F., Bourhis, J., Ducreux, M. P., Gaujoux, S., Gorphe, P., Guiu, B., Bessard, A. C. H., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.03.009 · Cited by 3
COVID-19 and the Cancer Patient
Ianniello, N. (2021) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2021.13.001916 · Cited by 1
“As of 2021, there are currently two mRNA vaccines and one recombinant adenovirus vector vaccine approved for COVID-19 under Emergency Use Authorization in the United States [5-7].”
BackgroundPardieck, I. N., van der Gracht, E. T. I., Veerkamp, D. M. B., Behr, F. M., van Duikeren, S., Beyrend, G., Rip, J., Nadafi, R., van der Sluis, T. C., Nejad, E. B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.15.472838 · Cited by 1
“Vaccines eliciting neutralizing antibodies against the Spike protein of SARS-CoV-2 have shown high effectiveness (1, 2).”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.